Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
Will the recent negative trend continue leading up to its next earnings release, or is Sarepta Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Q1 Earnings & Sales Beat Estimates Sarepta reported adjusted earnings of 73 cents per share in the first quarter of 2024. The Zacks Consensus Estimate was pegged at a loss of 11 cents per share. In the year-ago period, the company posted adjusted loss of 99 cents. The adjusted bottom-line figures exclude depreciation and amortization costs and stock-based compensation expenses. Including these items, earnings per share were 37 cents against the year-ago period's loss of $5.86. Sarepta recorded total revenues of $413.5 million, up 63% year over year. The upside was driven by sales of its four approved marketed therapies for DMD. The top line beat the Zacks Consens
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Global Cell and Gene Therapy CRO Market Research 2024-2035: Over 105 CROs Drive Innovations with 80% Ensuring Comprehensive Support from R&D to Clinical Trials [Yahoo! Finance]Yahoo! Finance
- Parent Project Muscular Dystrophy Hosts 30th Annual Conference in Orlando, Florida [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at Evercore ISI from $139.00 to $185.00. They now have an "in-line" rating on the stock.MarketBeat
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at SVB Leerink LLC from $165.00 to $230.00. They now have an "outperform" rating on the stock.MarketBeat
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target raised by analysts at BMO Capital Markets from $170.00 to $200.00. They now have an "outperform" rating on the stock.MarketBeat
SRPT
Earnings
- 5/1/24 - Beat
SRPT
Sec Filings
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- SRPT's page on the SEC website